Applied DNA Sciences Past Earnings Performance
Past criteria checks 0/6
Applied DNA Sciences has been growing earnings at an average annual rate of 5.7%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 32.4% per year.
Key information
5.7%
Earnings growth rate
61.5%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 32.4% |
Return on equity | -177.0% |
Net Margin | -81.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%
Dec 20Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?
Jan 01Applied DNA climbs 51% after winning large purchase order
Oct 10Applied DNA stock rises 12% on launching monkeypox testing service in New York
Sep 06Applied DNA adds 17% as company seeks approval for monkeypox test in New York
Aug 19Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
Aug 17Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise
Aug 09Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test
Aug 02Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19
Jul 25News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
May 18Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Deliver On Growth Plans?
Sep 17Applied DNA's LinearDNA COVID-19 vaccine booster yields 5-fold increase in neutralizing antibody in felines
May 06Revenue & Expenses BreakdownBeta
How Applied DNA Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 9 | -7 | 13 | 4 |
30 Sep 23 | 13 | -10 | 13 | 4 |
30 Jun 23 | 16 | -7 | 13 | 4 |
31 Mar 23 | 18 | -5 | 13 | 4 |
31 Dec 22 | 19 | -7 | 13 | 4 |
30 Sep 22 | 18 | -8 | 15 | 4 |
30 Jun 22 | 18 | -12 | 15 | 4 |
31 Mar 22 | 15 | -15 | 15 | 5 |
31 Dec 21 | 12 | -14 | 14 | 4 |
30 Sep 21 | 9 | -14 | 13 | 4 |
30 Jun 21 | 6 | -14 | 12 | 4 |
31 Mar 21 | 5 | -14 | 12 | 4 |
31 Dec 20 | 3 | -15 | 11 | 4 |
30 Sep 20 | 2 | -13 | 10 | 3 |
30 Jun 20 | 3 | -10 | 10 | 3 |
31 Mar 20 | 5 | -9 | 9 | 3 |
31 Dec 19 | 5 | -8 | 9 | 3 |
30 Sep 19 | 5 | -9 | 10 | 3 |
30 Jun 19 | 5 | -11 | 12 | 3 |
31 Mar 19 | 4 | -12 | 12 | 3 |
31 Dec 18 | 4 | -12 | 12 | 3 |
30 Sep 18 | 4 | -12 | 11 | 3 |
30 Jun 18 | 4 | -11 | 11 | 3 |
31 Mar 18 | 5 | -11 | 11 | 3 |
31 Dec 17 | 4 | -12 | 13 | 3 |
30 Sep 17 | 5 | -13 | 14 | 2 |
30 Jun 17 | 5 | -12 | 13 | 3 |
31 Mar 17 | 4 | -13 | 12 | 3 |
31 Dec 16 | 4 | -13 | 12 | 4 |
30 Sep 16 | 4 | -12 | 11 | 4 |
30 Jun 16 | 7 | -10 | 11 | 4 |
31 Mar 16 | 8 | -9 | 11 | 4 |
31 Dec 15 | 9 | -7 | 12 | 3 |
30 Sep 15 | 9 | -12 | 13 | 3 |
30 Jun 15 | 6 | -13 | 13 | 2 |
31 Mar 15 | 4 | -14 | 14 | 1 |
31 Dec 14 | 3 | -15 | 14 | 1 |
30 Sep 14 | 3 | -13 | 13 | 1 |
30 Jun 14 | 3 | -15 | 13 | 1 |
31 Mar 14 | 3 | -15 | 13 | 1 |
31 Dec 13 | 2 | -15 | 13 | 1 |
30 Sep 13 | 2 | -18 | 11 | 1 |
30 Jun 13 | 2 | -16 | 10 | 1 |
Quality Earnings: APDN is currently unprofitable.
Growing Profit Margin: APDN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APDN is unprofitable, but has reduced losses over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare APDN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APDN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: APDN has a negative Return on Equity (-177.04%), as it is currently unprofitable.